Clinical Trial Detail

NCT ID NCT03719430
Title APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Columbia University
Indications

leiomyosarcoma

sarcoma

liposarcoma

Therapies

APX005M + Doxorubicin + Olaratumab

Age Groups: adult senior

No variant requirements are available.